TPF

(Docetaxel, cisplatin, 5-fluorouracil)

Indication

Neoadjuvant/Induction therapy for Locally Advanced/Unresectable squamous cell carcinoma of the head and neck

Regimen details

Drug/dose	Fluid	Time
Docetaxel 75mg/m ²	250ml 0.9% sodium chloride	1 hour
Potassium chloride 20mmol & magnesium sulphate 10mmol	1 litre 0.9% sodium chloride	2 hours
Cisplatin 75mg/m ²	1 litre 0.9% sodium chloride	2 hours
Potassium chloride 20mmol & magnesium sulphate 10mmol	1 litre 0.9% sodium chloride	2 hours

Followed by:

5-fluorouracil 750mg/m²/day for 4 days via ambulatory infusor pump

Cycle frequency

Every 3 weeks

Number of cycles

2-3 cycles

Administration

Patients for outpatient pumps must have a PICC line inserted

Pre-medication

Dexamethasone 8mg bd for 3 days starting the morning before chemotherapy

Emetogenicity

Highly emetogenic

Investigations – pre first cycle

Audiometry (at discretion of consultant) Calculated Creatinine clearance (ClCr) FBC, U&Es, LFTs

DPD test (unless patient has previously received fluoropyrimidine-based SACT without issues)

Investigations -pre subsequent cycles

FBC, U&Es, LFTs Calculated Creatinine clearance Consultation prior to each cycle

Standard limits for administration to go ahead

If blood results not within range, authorisation to administer **must** be given by prescriber/ consultant.

Investigation	Limit
Neutrophil count	≥ 1.5 x 10 ⁹ /L (if 1-1.2 contact consultant)
Platelet count	$\geq 100 \times 10^9 / L$
Creatinine clearance	≥ 55mL/min
Bilirubin	≤ 1.5 x ULN
AST	< 1.5 x ULN

Dose modifications

If calculated creatinine clearance 50 – 55 reduce cisplatin dose by 20% If calculated creatinine clearance < 50 contact consultant

If DPD mutation positive then reduce 5FU dose as per network DPD guidelines

Adverse effects -

for full details consult product literature/ reference texts

Mucositis
Diarrhoea
Skin rashes
Neutropenic sepsis
Renal failure
High tone and hearing loss

5% - 10% incidence of precipitation of angina, chest pain must be taken seriously

THIS PROTOCOL HAS BEEN DIRECTED BY DR MIRZA, CLINICIAN FOR HEAD AND NECK CANCER

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

Date: JULY 2020 Review: JULY 2022

VERSION: 8